HOOK

HOOKIPA PharmaNasdaqGS:HOOK Stock Report

Market Cap

US$196.7m

7D

4.8%

1Y

-31.1%

Updated

22 Sep, 2021

Data

Company Financials +
HOOK fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

HOOK Overview

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform.

Price History & Performance

Summary of all time highs, changes and price drops for HOOKIPA Pharma
Historical stock prices
Current Share PriceUS$6.58
52 Week HighUS$6.01
52 Week LowUS$20.00
Beta1.1
1 Month Change-2.23%
3 Month Change-29.85%
1 Year Change-31.10%
3 Year Changen/a
5 Year Changen/a
Change since IPO-53.00%

Recent News & Updates

Jun 22

Checking Back In On HOOKIPA Pharma

Today, we revisit HOOKIPA Pharma for the first time in more than a year and a half. The company aims to develop a novel class of immunotherapeutics targeting infectious diseases and cancers based on their proprietary arenavirus platform that works by reprogramming the body's immune system. A full investment analysis follows in the paragraphs below.

Jun 08

Hookipa Pharma's HB-200 shows "positive" clinical efficacy in HPV16+ cancers

HOOKIPA Pharma (HOOK) has reported positive Phase 1 data from its ongoing Phase 1/2 study of HB-200 for the treatment of advanced Human Papillomavirus 16-positive (HPV16+) cancers.Up to the March 31 cut-off date, 38 patients with metastatic HPV16+ tumors had received HB-200 therapy: 14 received HB-201, 8 received alternating HB-201/HB-202, and 16 received other regimens.Immunogenicity data for eight patients with head and neck tumors were available at the time of data cut-off.  Arenaviral therapeutic HB-200 therapy induced outstanding tumor-specific CD8+ T

Shareholder Returns

HOOKUS BiotechsUS Market
7D4.8%-0.9%-1.7%
1Y-31.1%28.4%36.2%

Return vs Industry: HOOK underperformed the US Biotechs industry which returned 26.1% over the past year.

Return vs Market: HOOK underperformed the US Market which returned 31.5% over the past year.

Price Volatility

Is HOOK's price volatile compared to industry and market?
HOOK volatility
HOOK Beta1.1
Industry Beta1.03
Market Beta1

Stable Share Price: HOOK is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: HOOK's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2011123Joern Aldaghttps://www.hookipapharma.com

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers.

HOOKIPA Pharma Fundamentals Summary

How do HOOKIPA Pharma's earnings and revenue compare to its market cap?
HOOK fundamental statistics
Market CapUS$196.69m
Earnings (TTM)-US$60.45m
Revenue (TTM)US$19.88m

9.9x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HOOK income statement (TTM)
RevenueUS$19.88m
Cost of RevenueUS$71.43m
Gross Profit-US$51.55m
ExpensesUS$8.90m
Earnings-US$60.45m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.04
Gross Margin-259.28%
Net Profit Margin-304.07%
Debt/Equity Ratio3.8%

How did HOOK perform over the long term?

See historical performance and comparison

Valuation

Is HOOKIPA Pharma undervalued compared to its fair value and its price relative to the market?

1.56x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate HOOK's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate HOOK's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: HOOK is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: HOOK is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate HOOK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: HOOK is good value based on its PB Ratio (1.6x) compared to the US Biotechs industry average (3.2x).


Future Growth

How is HOOKIPA Pharma forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

7.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HOOK is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HOOK is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HOOK is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HOOK's revenue (53.3% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: HOOK's revenue (53.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HOOK is forecast to be unprofitable in 3 years.


Past Performance

How has HOOKIPA Pharma performed over the past 5 years?

-36.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: HOOK is currently unprofitable.

Growing Profit Margin: HOOK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HOOK is unprofitable, and losses have increased over the past 5 years at a rate of 36.6% per year.

Accelerating Growth: Unable to compare HOOK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HOOK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: HOOK has a negative Return on Equity (-48.01%), as it is currently unprofitable.


Financial Health

How is HOOKIPA Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: HOOK's short term assets ($143.5M) exceed its short term liabilities ($33.9M).

Long Term Liabilities: HOOK's short term assets ($143.5M) exceed its long term liabilities ($6.3M).


Debt to Equity History and Analysis

Debt Level: HOOK's debt to equity ratio (3.8%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if HOOK's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HOOK has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: HOOK has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 31.9% each year.


Dividend

What is HOOKIPA Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HOOK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HOOK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HOOK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HOOK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HOOK's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.5yrs

Average management tenure


CEO

Joern Aldag (62 yo)

5.25yrs

Tenure

US$1,924,036

Compensation

Mr. Joern Aldag has been Chief Executive Officer at Hookipa Biotech GmbH since June 16, 2016. He has been a Director of Hookipa Pharma Inc. since February 2017 and serves as its Chief Executive Officer sin...


CEO Compensation Analysis

Compensation vs Market: Joern's total compensation ($USD1.92M) is above average for companies of similar size in the US market ($USD1.09M).

Compensation vs Earnings: Joern's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: HOOK's management team is considered experienced (4.5 years average tenure).


Board Members

Experienced Board: HOOK's board of directors are considered experienced (3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.5%.


Top Shareholders

Company Information

HOOKIPA Pharma Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: HOOKIPA Pharma Inc.
  • Ticker: HOOK
  • Exchange: NasdaqGS
  • Founded: 2011
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$196.694m
  • Shares outstanding: 29.89m
  • Website: https://www.hookipapharma.com

Number of Employees


Location

  • HOOKIPA Pharma Inc.
  • 350 Fifth Avenue
  • 72nd Floor
  • New York
  • New York
  • 10118
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/22 22:45
End of Day Share Price2021/09/22 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.